Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia

American Journal of Hematology

Volumn 88, Issue 10, 2013, Pages 858-861

  Mahévas, Matthieu ^a   Ebbo, Mikael ^b   Audia, Sylvain ^c   Bonnotte, Bernard ^c   Schleinitz, Nicolas ^b   Durand, Jean Marc ^b   Chiche, Laurent ^b   Khellaf, Medhi ^a   Bierling, Philippe ^a   Roudot Thoraval, Françoise ^a   Godeau, Bertrand ^a   Michel, Marc ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLEEDING; BULLOUS PEMPHIGOID; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84884710634     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23518     Document Type: Article

References (19)

1. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
2. Martin F, Chan AC. B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-496.
3. Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960-969.
4. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
5. Auger S, Duny Y, Rossi JF, et al. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: A meta-analysis. Br J Haematol 2012;158:386-398.
6. Patel VL, Mahevas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989-5995.
7. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-1150.
8. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008;93:930-933.
9. Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007;92:1695-1698.
10. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010;85:329-334.
11. Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158-1161.
12. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012;8:505-514.
13. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-130.
14. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
15. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
16. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-239.
17. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-957.
18. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
19. Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012;87:886-889.